AbbVie, Johnson & Johnson grab another Imbruvica nod with early OK in rare blood cancer
admin 27th August 2018 Uncategorised 0Two months ahead of the FDA decision date, the agency approved AbbVie and J&J’s Imbruvica, plus Roche’s Rituxan, to treat adults with a rare blood cancer. The approval will provide patients and doctors with the first chemo-free option to treat the disease.
More: AbbVie, Johnson & Johnson grab another Imbruvica nod with early OK in rare blood cancer
Source: fierce